|Bid||50.83 x 800|
|Ask||50.97 x 1000|
|Day's Range||50.49 - 51.86|
|52 Week Range||33.40 - 87.45|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.71|
LivaNova PLC will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m. London time (7 a.m. EDT).
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
LivaNova PLC today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025.
LivaNova PLC announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 in private offering.
LivaNova PLC today announced its entry into a five-year $450m senior secured credit facility with funds managed by affiliates of Ares Management Corp.
Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]
LivaNova PLC announced Thad Huston, CFO, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern.
LivaNova PLC presented the first data from the Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study.
LivaNova PLC announced publication of a new study that showed positive impact from VNS Therapy for treatment-resistant bipolar depression.
LivaNova will present findings from its Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at AATS.
LivaNova announced Damien McDonald, CEO, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time.
The quarterly results for LivaNova PLC (NASDAQ:LIVN) were released last week, making it a good time to revisit its...
Joining me on today's call are Damien McDonald, our chief executive officer; Thad Huston, our chief financial officer; and Melissa Farina, our vice president of investor relations. After my comments, Thad will provide you with additional detail on the financials and our revised 2020 guidance.
Shares of LivaNova (NASDAQ:LIVN) were unchanged at $56.37 after the company reported Q1 results.Quarterly Results Earnings per share decreased 38.89% over the past year to $0.33, which missed the estimate of $0.43.Revenue of $242,400,000 lower by 3.35% year over year, which missed the estimate of $244,100,000.Guidance LivaNova hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Apr 29, 2020View more earnings on LIVNTime: 08:05 AM ETWebcast URL: https://edge.media-server.com/mmc/p/hrqp7xshRecent Stock Performance 52-week high: $87.45Company's 52-week low was at $33.40Price action over last quarter: down 18.17%Company Profile U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.See more from Benzinga * Alkermes: Q1 Earnings Insights * Recap: Saia Q1 Earnings * Sensient Technologies: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LivaNova announced many of its cardiopulmonary products are permitted for use in the U.S. for COVID-19 ECMO use greater than 6 hours per FDA guidance.
LivaNova PLC will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time (8 a.m. EDT).
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
LivaNova will share two abstracts focused on implantable neuromodulation technology for patients with heart failure during ACC.20/WCC Virtual.
LivaNova PLC today announced its VNS Therapy® System, Symmetry™, earned CE Mark approval for Difficult-to-Treat Depression.
NEW YORK, NY / ACCESSWIRE / February 26, 2020 / LivaNova PLC (NASDAQ:LIVN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 26, 2020 at 8:00 AM ...
It hasn't been the best quarter for LivaNova PLC (NASDAQ:LIVN) shareholders, since the share price has fallen 13% in...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]